BioWorld

Feb. 8, 2007

BioLineRx Prices $50M IPO, Listing On Tel Aviv Exchange

Israeli drug development firm BioLineRx Ltd. gained a listing on the Tel Aviv Stock Exchange and brought in $50 million in an oversubscribed initial public offering. (BioWorld Today) Read More

Proacta Completes $35M Series B For Hypoxia Trials

Encysive Sells $60M In Notes Secured By Argatroban Royalties

Biogen Idec Testing Targeted MAB In Pivotal CLL Study

Other News To Note

U.S. Patent Disclosures

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...